NDASUBLINGUALTABLET
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
2
Clinical Trials (2)
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
Started Dec 2025
50 enrolled
PharmakokineticOpen LabelPhase 1
Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine
Started Jul 2010
35 enrolled
Chronic Migraine
Loss of Exclusivity
LOE Date
Mar 14, 2034
97 months away
Patent Expiry
Mar 14, 2034
Exclusivity Expiry
Aug 15, 2028